A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling
一项针对转移性胰腺癌的 XL888(HSP90 抑制剂)联合帕博利珠单抗的 Ib/II 期临床试验,并结合转化免疫分析。
期刊:Cancer Letters
影响因子:10.1
doi:10.1016/j.canlet.2025.218233
Horvat, Natalie K; Diab, Maria; Phillips, Maggie J; McCook-Veal, Ashley; Grundy, Erin E; Alese, Olatunji B; Greene, Emily; Gbolahan, Olumide; Coleman, Kathleen; Doxie, Deon; Herting, Cameron J; Hammons, Jacklyn; Mahdi, Zaid; Switchenko, Jeffrey M; Paulos, Chrystal M; El-Rayes, Bassel F; Lesinski, Gregory B